{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,3,31]],"date-time":"2024-03-31T21:11:11Z","timestamp":1711919471135},"reference-count":5,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2010,10,28]],"date-time":"2010-10-28T00:00:00Z","timestamp":1288224000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2010,11]]},"DOI":"10.1007\/s12185-010-0711-9","type":"journal-article","created":{"date-parts":[[2010,10,27]],"date-time":"2010-10-27T00:28:33Z","timestamp":1288139313000},"page":"673-674","source":"Crossref","is-referenced-by-count":0,"title":["Postremission gemtuzumab ozogamicin for elderly patients with acute myelogenous leukemia with favorable characteristics and comorbid conditions"],"prefix":"10.1007","volume":"92","author":[{"given":"Motoshi","family":"Ichikawa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akira","family":"Hangaishi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuhito","family":"Nannya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mineo","family":"Kurokawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2010,10,28]]},"reference":[{"key":"711_CR1","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1056\/NEJMoa0901409","volume":"361","author":"B L\u00f6wenberg","year":"2009","unstructured":"L\u00f6wenberg B, Ossenkoppele GJ, van Putten W, Schouten HC, Graux C, Ferrant A, et al. High-dose daunorubicin in older patients with acute myeloid leukemia. N Engl J Med. 2009;361:1235\u201348.","journal-title":"N Engl J Med"},{"key":"711_CR2","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1056\/NEJMoa0904544","volume":"361","author":"HF Fernandez","year":"2009","unstructured":"Fernandez HF, Sun Z, Yao X, Litzow MR, Luger SM, Paietta EM, et al. Anthracycline dose intensification in acute myeloid leukemia. N Engl J Med. 2009;361:1249\u201359.","journal-title":"N Engl J Med"},{"key":"711_CR3","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1111\/j.1365-2141.2010.08168.x","volume":"150","author":"A Poloni","year":"2010","unstructured":"Poloni A, Capelli D, Trappolini S, Costantini B, Montanari M, Gini G, et al. Low-dose gemtuzumab\u2013ozogamicin as post-consolidation therapy in elderly patients with acute myeloid leukaemia: a pilot study. Br J Haematol. 2010;150:119\u201320.","journal-title":"Br J Haematol"},{"key":"711_CR4","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.leukres.2008.05.006","volume":"33","author":"AR El Kinge","year":"2009","unstructured":"El Kinge AR, Hatoum HA, Mahfouz RA, Otrock ZK, Jabbour E, Kantarjian H, et al. Gemtuzumab ozogamicin is a promising post-remission therapy for acute myeloid leukemia. Leuk Res. 2009;33:565\u20136.","journal-title":"Leuk Res"},{"key":"711_CR5","doi-asserted-by":"crossref","first-page":"2586","DOI":"10.1182\/blood-2009-10-246470","volume":"115","author":"B L\u00f6wenberg","year":"2010","unstructured":"L\u00f6wenberg B, Beck J, Graux C, van Putten W, Schouten HC, Verdonck LF, et al. Gemtuzumab ozogamicin as postremission treatment in AML at 60\u00a0years of age or more: results of a multicenter phase 3 study. Blood. 2010;115:2586\u201391.","journal-title":"Blood"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-010-0711-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12185-010-0711-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-010-0711-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,31]],"date-time":"2024-03-31T20:55:30Z","timestamp":1711918530000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12185-010-0711-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,10,28]]},"references-count":5,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2010,11]]}},"alternative-id":["711"],"URL":"https:\/\/doi.org\/10.1007\/s12185-010-0711-9","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,10,28]]}}}